Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Genzyme Corporation 

500 Kendall Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-252-7500 Fax: 617-252-7600


About Genzyme

Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before.

Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients.

Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis.

Learn more at

Follow our jobs on Twitter

Follow us on LinkedIn

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

 Key Statistics

Ownership: Public

Web Site: Genzyme
Symbol: GENZ



Medtronic  Cardiac Cell Therapy

Cambridge Antibody Technology Group PLC   Antibodies against TGF-ß

Dyax Corp.  Hereditary Angioedema


 Company News
Genzyme (GENZ)’s Announces Launch Of Expression Of Hope III Art Exhibit 5/20/2015 12:24:30 PM
Genzyme (GENZ) Receives Innovation Award From The National Organization For Rare Disorders (NORD) For The Development Of Cerdelga 5/19/2015 11:08:34 AM
FDA Grants Fast Track Designation To Genzyme (GENZ)’s Investigational Substrate Reduction Therapy For The Treatment Of Fabry Disease 4/28/2015 10:31:49 AM
Effect Of Genzyme (GENZ)’s Multiple Sclerosis Treatment Lemtrada (Alemtuzumab) On Slowing Brain Atrophy And MRI Lesion Activity Maintained Through Four Years 4/23/2015 8:42:28 AM
Genzyme (GENZ) Initiates Phase 2a Clinical Trial To Evaluate Oral Therapy For Fabry Disease 4/21/2015 8:50:24 AM
Newton North High School Students Explore STEM Career Opportunities At Genzyme (GENZ) 4/16/2015 12:09:27 PM
Cystic Fibrosis Foundation Therapeutics, Inc. Announces $14 Million Research Expansion With Genzyme (GENZ) 4/16/2015 10:17:10 AM
Genzyme (GENZ) To Present New Long-Term Data On Aubagio (teriflunomide) And Lemtrada (alemtuzumab) At American Academy of Neurology 4/13/2015 8:39:20 AM
Genzyme (GENZ) Not Moving Yet But Kendall Square Space Already Getting Massive Interest 4/2/2015 6:26:08 AM
Genzyme (GENZ)’s Cerdelga (eliglustat) Capsules Approved In Japan 3/30/2015 10:25:23 AM